ImmuCell and Pinetree Capital Reveal 2025 Results Amid Scaling Shift
ImmuCell (ICCC) has issued its preliminary 2025 financial results, highlighting a year of operational scaling for its bovine immunity products. Simultaneously, major shareholder Pinetree Capital Ltd released audited figures and expanded its board, signaling a period of strategic consolidation for the animal health biotech and its primary backer.